P ercutaneous coronary intervention (PCI) is the most common strategy for myocardial revascularization and in the vast majority of the cases is accomplished with coronary stenting. To prevent the occurrence of stent thrombosis and its serious clinical consequences, dual antiplatelet therapy is recommended for at least 1 month after bare-metal stent (BMS) implantation and for 6 to 12 months after drug-eluting stent (DES) implantation. 1-3 This different therapeutic approach is because of delayed endothelialization associated with DES, a phenomenon that extends the time window for the risk of stent thrombosis.
with an inverse relationship with time. 6 Indeed, premature cessation of dual antiplatelet therapy is a strong predictor of stent thrombosis, and surgery is a common reason for premature discontinuation of either single or dual antiplatelet therapy (DAPT) antiplatelet therapy. 7 The hypercoagulable state associated with surgery can further contribute to increase the overall ischemic risk. On the opposite front, continuation of antiplatelet therapy may increase the risk of perioperative bleeding. 8 The risk of perioperative complications, however, depends also on other factors, including patient status, type, and magnitude of surgery and prevalence of comorbidities. 3 Cardiac risk, therefore, extends well beyond the recommended period of dual antiplatelet therapy. Further, the influence of stent type and period of risk still have to be defined, and a recent study did not show temporal differences in outcomes between DES and BMS for at least 2 years after PCI. 4 The aims of this study were to describe the incidence and type of cardiac (CS) and noncardiac surgery (NCS) after PCI and stenting during long-term follow-up and to assess predictors of periprocedural adverse ischemic and bleeding events. In addition, we sought to assess the risk associated with the interplay between different stent types and time from stenting to surgery.
Methods

Patient Population and Surgical Procedures
Among 39 362 consecutive patients undergoing PCI and stenting between July 2002 and December 2011 enrolled in the all comers multicenter Registro regionale AngiopLastiche dell'Emilia-Romagna (REAL) Registry, [9] [10] [11] [12] we identified those who underwent surgery up to December 31, 2012 (median follow-up 4.8 years, interquartile range 2.8-6.9 years). As previously reported, [9] [10] [11] [12] for reimbursement and health policy issues, the Regional Healthcare and Social Agency of the Region Emilia-Romagna is able to identify all hospital admissions occurring within the entire Italian country for patients who are resident in the Region. This ensures a complete follow-up for all patients enrolled in the registry, with a maximum delay of 1 year. Surgical procedures occurring abroad, which are known to be extremely rare, could theoretically be missed. Follow-up is updated every 3 months. In addition, the Regional Government, through the analysis of mortality registries, keeps track of vital status of all patients who are resident in the region and is able to identify all deaths occurring within and outside the national territory. A total of 1512 types of interventions and 17 226 elective or urgent surgical procedures of interest were identified. Surgery was divided into CS and NCS. Distinction between elective and urgent surgery was reported in the hospital discharge records. Electrophysiology procedures with a surgical approach (eg, pace maker implantation and implantation of implantable cardiac defibrillator) were taken into account to assess the overall incidence of surgery but were excluded from multivariable analyses.
End Points and Definitions
Cardiac risk associated with each surgical procedure was classified according to current European Society of Cardiology guidelines as low, intermediate or high based on estimated 30-day cardiac event rates ( Table I in 13 For this purpose, a large number of surgeons were previously involved, and the result of this multidisciplinary collaboration have been summarized in an intersociety consensus document on perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation. The document was endorsed by 16 national societies of cardiology, anaesthesiology, and surgery. Stent thrombosis risk associated with previous stenting was categorized based on the type of stent implanted (BMS versus DES) and time between index PCI and surgery. Stent thrombosis risk was defined low >6 months after BMS and >12 months after DES; intermediate 1 to 6 months after BMS or 6 to 12 months after DES; and high <1 month after BMS or <6 months after DES (Table 1) . 13 For patients with multiple PCI procedures, only the procedure carrying the highest thrombotic risk based on the classification above was selected for the analysis. In patients undergoing surgery, the incidence of cardiovascular death, myocardial infarction (MI), and serious bleeding event (SBE) was assessed at 30 days. Follow-up was obtained directly and independently from the Emilia-Romagna Regional Healthcare and Social Agency through the analysis of the Hospital Discharge Records and the Mortality Registries. This administrative process ensures complete follow-up for all the patients who are resident in the Region, provided they are admitted in an Italian hospital. Follow-up for mortality comprises out-of-hospital deaths. Cardiac death was defined as the combination of death from a clearly identifiable cardiovascular cause or sudden/unexplained death. An SBE was defined as hemorragic stroke and any bleeding requiring intervention or unplanned red blood cell transfusion or leading to death or a new hospitalization. 14 Repeated PCI was collected both from hospital discharge records and from the prospective REAL registry database, which collects data from 13 catheterization laboratories. There was no formal event adjudication, and so all events were diagnosed by physicians involved in patients' care.
Statistical Analysis
Continuous variables were expressed as mean±SD and compared using Student's unpaired t test. Categorical variables were expressed as counts and percentages, and χ 2 test was used for comparison.
WHAT IS KNOWN
• In patients with coronary stents, surgery carries a considerable risk of ischemic and bleeding events.
• In the perioperative phase, discontinuation of antiplatelet therapy increases the risk of stent thrombosis and cardiac ischemic events, in general, whereas continuation of antithrombotics increases the risk of bleeding.
• Bare-metal stents are usually preferred for coronary revascularization when surgery is planned at the time of percutaneous coronary intervention.
WHAT THE STUDY ADDS
• Surgery is frequent during follow-up of patients with previous coronary stenting, and its incidence is generally underestimated.
• Perioperative ischemic risk is inversely related with time from percutaneous coronary intervention to surgery and is influenced by stent type, with new-generation drug-eluting stent appearing at least as safe as bare-metal stent at any time window.
The incidence of surgery during follow-up was estimated with the Kaplan-Meier method. To estimate the cumulative incidence of surgery, only the first surgery was used as the event of interest without considering recurrent events. Multivariate time-dependent Cox regression analysis was performed to identify factors independently associated with cardiac detah during follow-up, using all clinical, angiographic, and procedural variables included in Table 2 . Surgery and treatment were used as time-dependent covariates. Considering surgery as a time-varying variable enable to avoid immortal time bias 15 by acknowledging a change in exposure status: all patients were considered unexposed (ie, without surgery) from the time of study entry until the date of surgery; patients who received surgery were considered exposed from the time of surgery until death or the end of the study. 16 Differently, the incidence of adverse events within 30 days was calculated for every single surgical procedure, including repeated interventions. Accordingly, to estimate odds ratios (OR) for events of interest, stent thrombosis risk, surgical risk, and bleeding risk were reclassified for each single surgical procedure (see examples in the Data Supplement). Stepwise multivariable logistic regression analyses were performed to identify predictors of cardiac death/ MI or SBE within 30 days from surgery, using the following variables with a probability of inclusion =10%: urgent surgery, thrombotic risk, bleeding risk, surgical risk, age, sex, diabetes mellitus, liver cirrhosis, hypertension, cerebrovascular disease, chronic kidney disease, cancer, chronic obstructive pulmonary disease, previous red blood cell transfusion, diagnosis at admission for PCI, ejection fraction, target vessel, total lesion length, heart failure, and NCS versus CS. The first 4 variables were forced into the model. Additional variables that were not significant at univariable analyses, such as in-stent restenosis, chronic total occlusion, bifurcation, stent size, and total stent length, were not included in the final multivariable analyses. Model discrimination was measured using the c-statistic, and calibration was estimated using the Hosmer-Lemeshow statistic. A second multivariable analysis was performed replacing the variable stent thrombosis risk with the following variables: BMS >360 days (reference, hazard ratio =1), oDES >360 days, nDES >360 days, BMS 180 to 360 days, oDES 180 to 360 days, nDES 180 to 360 days, BMS 0 to 180 days, oDES 0 to 180 days, and nDES 0 to 180 days. The statistical threshold for significance was set at P<0.05 for a 2-tailed test. All analyses were performed with the SAS 9.3 system (SAS Institute, Cary, NC).
This study was based on common practice, and regulatory authorities required written informed consent for PCI and for data collection, which was obtained for all patients. The study protocol is in accordance with the declaration of Helsinki.
Results
During follow-up after PCI and stenting, a total of 13 128 patients underwent 17 226 surgical procedures (6085 [35.3%] <12 months from PCI). The cumulative incidence of any surgery at 30 days, 6 months, 1 year, and 5 years was 3.6%, 9.4%, 14.3, and 40.0%, respectively. The cumulative incidence of CS and NCS during follow-up is shown in Figure 1 . At 30 days, 6 months, and 1 year, the cumulative incidence of NCS was 1.3%, 5.1%, and 9.1% and of CS was 0.8%, 2.1%, and 2.6%, respectively. Overall, 79.8% of surgical procedures were noncardiac (Table 3 ). Around a third of the procedures (29.0%) were done on an urgent basis, with a wide range between different types of surgery (from 4.7% eye surgery to 53.1% electrophysiology; Figure I in the Data Supplement). The cumulative rates of urgent procedures at 30 days, 6 months, and 1 year were 2.7%, 4.5%, and 5.7%, respectively. The corresponding rates of nonurgent procedures were 0.9%, 5.0%, and 8.7%, respectively. Table 2 describes the baseline characteristics of patients who underwent surgery during follow-up in comparison to those who did not. BMS was used more often in patients who underwent surgery <1 year from PCI ( Table III in Within 30 days after surgery, death occurred in 754 patients (4.4%), cardiac death in 438 (2.5%), nonfatal MI in 256 (1.5%), and an SBE in 1099 (6.4%). Bleeding was fatal in 115 cases (10.5% of all SBE). Tables IV and V in the Data Supplement show the differences between patients who had perioperative events versus those who did not. The independent predictors of cardiac death/MI and SBE at 30 days are illustrated in Figure 3 . Of interest, thrombotic risk was independently associated with periprocedural cardiac death/ MI (OR=1.50 for intermediate risk and 2.17 for high risk), whereas surgical risk and bleeding risk were not. Conversely, stent thrombosis risk was not independently associated with periprocedural SBE, whereas operative risk category was a significant predictor of SBE (OR=1.62 for intermediate risk and 1.75 for high risk), and bleeding risk category was strongly related to SBE (OR=2.27 for intermediate risk and 4.09 for high risk). The interaction between stent type and timing from stenting to surgery showed an increased risk of ischemic events with oDES at any time point (0-180 days from PCI, OR=2.10; 6-12 months OR=1.90; >12 months OR=1.45; Figure 3C ; Table VI in the Data Supplement). BMS and nDES were not significantly different >12 months and between 6 and 12 months after PCI, whereas nDES appeared somewhat safer between 0 and 180 days. A further analysis including the time frames 0 to 60 days and 60 to 180 days demonstrated that this advantage is all achieved beyond 2 months after stenting, a time frame where nDES have a neutral effect, whereas BMS and oDES significantly increased the risk (OR=1.45 and 2.41, respectively; Figure II in the Data Supplement). Sensitivity analyses excluding the Endeavor stent confirmed these results (Tables VII and VIII and Figure III in the Data Supplement) . Finally, we evaluated the overall effect of surgery and timing of surgery with respect to PCI over cardiovascular mortality during follow-up and found that surgery was associated with an increased risk (hazard ratio =1.58), which was strongly influenced from the time span between PCI and surgery ( 
Discussion
The principal findings of our population-based study can be summarized as follows: (1) around 14% of the patients who received coronary stents underwent surgery during the first year after the procedure and 40% did so within 5 years; (2) surgery is associated with an increased risk of cardiovascular mortality during follow-up; (3) around 18% of the surgical procedures carry a high cardiac risk and 25% a high bleeding risk, and in 12% of the cases surgery is performed in patients with a high risk of stent thrombosis; (4) urgent surgery is a strong predictor of both ischemic and bleeding events in the periprocedural phase; (5) along with conventional risk factors, thrombotic risk associated with the interplay between type of stent and time from PCI to surgery provides reliable risk stratification for the occurrence of cardiac death/MI within 30 days after surgery; (6) nDES seem safer than oDES and BMS when surgery is performed between 0 and 6 months after PCI and safer than oDES and comparable to BMS between 6 and 12 months and beyond 1 year.
The incidence of NCS within 1 year after PCI is commonly reported to be around 5%. 2, 4, 17, 18 In our study, we found that this proportion was definitely higher, being around 9% for NCS and around 14% including CS and surgical electrophysiology procedures, which is consistent with findings of a recent study based on the Veterans Administration databases. 19 The fact that around 35% of surgical procedures recorded were performed <12 months from PCI and that ≤40% of the patients needed surgery within 5 years after stenting describes the magnitude of the problem for perioperative risk management. In these patients, the tradeoff between reduction of ischemic risk with antithrombotics and increased bleeding risk is difficult, and in many instances, therapeutic decisions are arbitrary and not evidence-based. To minimize ischemic risk, current guidelines provide a general recommendation that elective surgery be delayed until 30 to 45 days after BMS implantation and 1 year after DES, 1,2 whereas elective NCS may be considered beyond 6 months after DES in selected cases but is generally discouraged. Yet, surgery represents a common reason for early discontinuation of DAPT, a relevant risk factor for stent thrombosis, and the first cause of late (>12 months) discontinuation of aspirin because of the concerns of perioperative bleeding. 7 It is worth noting that the risk of stent thrombosis and adverse ischemic events persists for inpatient surgery >12 months after PCI, especially for DES, extending at least 2 to 3 years. 20 In addition, aspirin withdrawal at any time has been associated with an adverse prognosis in subjects with coronary artery disease 8 and coronary stents. 21 On the other hand, previous studies suggested that continuation of antiplatelet therapy until surgery does not provide complete protection against ischemic events 22 and may actually increase bleedings, 23 especially for some types of procedures. 6 Our study confirms that careful cardiovascular risk stratification, including assessment of intrinsic surgical cardiac risk, bleeding risk, and thrombotic risk associated with the stent, may be helpful in predicting the risk of periprocedural events and should always be adopted (Figure 3) . Although there is a general agreement on surgical risk estimate for the principal surgical procedures, 3 a standardization of bleeding risk and ischemic risk associated with the type of stent implanted and the time elapsed from PCI is missing. For the purpose of this study, expert surgeons classified bleeding risk and their classification actually reflected the risk of SBEs ( Figure 3B) , with a more than double risk of SBE in patients at intermediate risk and a 4.09× higher risk in patients deemed at high risk.
Considering the fact that SBEs were numerically higher than cardiac death and MI, a standardized bleeding classification of surgical procedures seems helpful, and interesting attempts in this direction are ongoing. 13 In our study, thrombotic risk stratification on the basis of stent type (DES versus BMS) and time from PCI showed a good correlation with the incidence of cardiac death/MI within 30 days after surgery ( Figure 3A) . Patients with intermediate thrombotic risk exhibited a 50% higher risk of cardiac death and MI, and patients classified at high risk showed a risk of cardiac death/MI 2.17× higher than patients at low thrombotic risk. Two recent studies suggested that 6 months might be the earliest optimal time for surgery after DES implantation. 24, 25 Our findings support guidelines' emphasis on stent type and surgical timing and raise the hypothesis that further risk stratification could be performed with differentiation between oDES and nDES ( Figure 3C ). Indeed beyond 1 year after implantation, there was no apparent difference between BMS and nDES (whereas for oDES, there was still an increased risk).
Similarly, focusing on the interval between 6 and 12 months, the risk of cardiac death and MI seems significantly higher with oDES (OR=1.90), whereas it was comparable between BMS and nDES (and numerically lower than with BMS >12 months, a timing when restenosis could be detrimental for BMS). These observations are consistent with several reports of improved vessel healing and reduced stent thrombosis risk associated with new generation DES. 26 Remarkably, nDES was not associated with a significant increase of death and MI when surgery was performed within 6 months from PCI, whereas the risk for BMS (OR=2.00) and oDES (OR=2.10) was higher. A further analysis demonstrated that this potential advantage of nDES was gained between 2 and 6 months after stenting. Possible explanation for this apparent better safety of nDES even when surgery occurs early after PCI may be the thinner stent struts design and the presence of thromboresistant or bioabsorbable polymers. Further studies are necessary to better investigate these findings. In this scenario, it is worth mentioning that shorter duration of mandatory dual antiplatelet therapy after nDES has been approved in many countries and that the current attitude to prefer BMS in patients who are candidates for elective surgery could be challenged.
As previously mentioned, our study further highlight the need for dedicated pharmacological strategies aimed at minimizing both ischemic and bleeding risk in patients with coronary stents undergoing surgery. A bridging strategy using the short-acting glycoprotein IIb/IIIa inhibitor tirofiban has been proposed for patients at high risk for stent thrombosis undergoing urgent surgery. 27 Although initial results are promising, this strategy has important potential drawbacks, including excessive level of antiplatelet inhibition and slow return to baseline platelet function, and convincing evidence is still lacking. An attractive alternative is cangrelor, an intravenous antagonist of the Adenosine diphosphate P2Y 12 receptor characterized by rapid and reversible platelet inhibition and fast (<1 hour) offset of effect. In a randomized trial, among patients undergoing CS who discontinued thienopyridine therapy, cangrelor was shown superior to placebo in maintenance of platelet inhibition throughout the periprocedural phase, without increasing major bleedings. 28 Clinical efficacy of this strategy in patients undergoing CS and NCS must be confirmed in larger studies.
This study presents several limitations because of its retrospective nature. Most importantly, we did not have information on pharmacological treatment at the time of surgery and in patients with adverse events, so our study must be viewed as a picture of current situation assuming that physicians did their best to minimize the risk of perioperative adverse events. Adverse events occurring in patients scheduled to undergo surgery while preparing for surgery (ie, while stopping DAPT) were not captured unless the patient was already hospitalized, thus possibly underestimating the ischemic risk. Some of the findings about different stent types might have been influenced by different pharmacological choices rather than the stent type itself. Although our analysis took into account a large number of surgical procedures, outpatient surgery and invasive diagnostic procedures were not captured. These procedures are associated with a low risk of major complications and in most of the cases can be performed while patients receive DAPT or delayed until DAPT is no longer necessary, but they are not infrequently the cause of premature antiplatelet discontinuation. Finally, use of DES was generally low, reflecting average use in our catheterization laboratories during the study period. However, the general validity of our findings should not be influenced by this premise, being the absolute number of patients enrolled and surgical procedures considered high enough to allow reliable multivariable analyses. Yet, the number of patients treated with nDES in relationship with other subgroups is small, and this expose to a sizable risk of type II error. Hence, our findings about nDES can only be viewed as hypothesis generating.
Conclusions
Surgery is frequent in patients with coronary stents and poses important problems for perioperative management. Stratification of thrombotic and bleeding risk may help decisionmaking for the most appropriate perioperative management. nDES seem safer than oDES when surgery is performed <1 year after PCI and at least as safe as BMS at any time point.
